Story perspectives

GLP-1 Drugs Ignite Nutraceutical Innovation for Millions

11/29/2025

Summary

Story summary

Glucagon-like peptide-1 (GLP-1) drugs emerged as a key trend at the SupplySide Global 2025 show, with 30 to 50 million potential U.S. users.
The convenience has spurred interest from ingredient manufacturers to develop supportive products.
Users face appetite suppression and nutritional deficiencies.
Innovations like Oleoylethanolamide (OEA) and Eriomin aim to boost GLP-1 production and aid withdrawal.
Nutraceuticals address side effects and support muscle mass and overall nutrition for GLP-1 users.

1 of 1

Story summary

Glucagon-like peptide-1 (GLP-1) drugs emerged as a key trend at the SupplySide Global 2025 show, with 30 to 50 million potential U.S. users.
The convenience has spurred interest from ingredient manufacturers to develop supportive products.
Users face appetite suppression and nutritional deficiencies.
Innovations like Oleoylethanolamide (OEA) and Eriomin aim to boost GLP-1 production and aid withdrawal.
Nutraceuticals address side effects and support muscle mass and overall nutrition for GLP-1 users.